Jasman Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-12-2024
- Paid Up Capital ₹ 0.10 M
as on 08-12-2024
- Company Age 5 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2022)
- Profit 80.39%
(FY 2022)
- Ebitda 80.39%
(FY 2022)
- Net Worth -658.96%
(FY 2022)
- Total Assets -2.48%
(FY 2022)
About Jasman Pharmaceuticals
The Company is engaged in the Home & Lifestyle Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dharmendra Kumar, Kumar Saurabh, Abhishek Jaiswal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24304UP2019PTC124015
- Company No.
124015
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
02 Dec 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Sitapur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jasman Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhishek Jaiswal  | Director | 02-Dec-2019 | Current |
| Dharmendra Kumar | Director | 02-Dec-2019 | Current |
| Kumar Saurabh | Director | 02-Dec-2019 | Current |
| Manish Singh | Director | 02-Dec-2019 | Current |
Financial Performance of Jasman Pharmaceuticals.
Jasman Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 80.39% increase in profit. The company's net worth observed a substantial decline by a decrease of 658.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jasman Pharmaceuticals?
Unlock access to Jasman Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Quantum Path Labs Limited Liability Part NershipActive 4 years 6 months
Manish Singh is a mutual person
- Twenty Four Seven Health Services Private LimitedActive 5 years 7 months
Manish Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jasman Pharmaceuticals?
Unlock and access historical data on people associated with Jasman Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jasman Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jasman Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
